Aenova is the company formed by the merger of two separate investments made by Bridgepoint: Swiss Caps, Europe’s No 2 contract soft capsule manufacturer of vitamins, minerals, supplements and pharma products, and Dragenopharm, a German contract manufacturer for the generic prescription drugs market.
| Office | Frankfurt | ||
| Acquired | 2006 | Deal size | N/D |
Formed in 2006, Aenova now has the largest contract tablet manufacturing capacity in Europe for perscription and OTC drugs and nutritional supplements and is a leading producer of generic drugs. Combining both businesses created the opportunity to improve manufacturing efficiency, and through sharing technological know-how and IP, accelerate both product development and expansion of its customer base.
Under Bridgepoint ownership the company became a key partner for many of Europe's leading pharmaceutical companies.
In August 2012 Aenova was acquired by BC Partners for an undisclosed sum.
To learn more about the company, visit www.aenova.de
